Not all genetic tests are created equal, and the difference is not just price or brand. The right test depends on the question being asked: confirming a known family mutation, hunting for an unknown cause of a complex condition, or exploring drug-response variants. According to The Jackson Laboratory's clinical education resources, tests range from narrowly targeted analyses to whole-genome sequencing, each detecting different variant types. Meanwhile, the National Human Genome Research Institute distinguishes two very different access pathways—direct-to-consumer and provider-mediated—that determine who orders the test, what oversight exists, and whether results can guide medical decisions.
Understanding Genetic Testing Technologies
Genetic tests differ primarily in analytical scope: how much of the genome they examine and which kinds of variation they can detect. The Jackson Laboratory's comparison of clinical tests lays out a clear hierarchy. Targeted mutation analysis interrogates specific known variants or a limited set of genes, and despite its narrow focus it can detect a wide range of variant classes within those regions—single nucleotide variants (SNVs), insertions and deletions (indels), copy number variants (CNVs), trinucleotide repeats (TNRs), methylation changes, and mitochondrial DNA. Condition-specific panels share this broad detection capability while covering the genes linked to a particular disorder.
Broad multi-gene tests, by contrast, cast a wider net but detect fewer variant classes—typically SNVs and indels only, according to the same comparison. Exome sequencing reads all protein-coding regions, which represent roughly 1–2% of the genome yet contain most known disease-causing variants; it also primarily detects SNVs and indels, meaning it may miss variants in non-coding regions or large structural rearrangements. Genome sequencing covers coding and non-coding regions alike and adds mitochondrial DNA to the SNV and indel detection shared by exome testing, providing the most comprehensive view of an individual's genetic makeup.
A narrative review of genomic medicine published in 2025 situates these technologies historically: next-generation sequencing—including whole-genome, whole-exome, whole mitochondrial, targeted exome, and RNA sequencing—has countered the limitations of older methods like Sanger sequencing, karyotyping, and chromosomal arrays for rare genetic diseases. The scale of exome sequencing is illustrated by the UK Biobank, where whole-exome sequencing of roughly 500,000 individuals identified about 564 distinct genes with significant trait associations, from CHD2 in B-cell chronic lymphocytic leukemia to COL1A1 in bone disorders and SERPINC1 in coagulation defects. The Jackson Laboratory notes a general principle: as a test's scope increases, its diagnostic yield also increases.





